Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Apr 30, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

A mouse bleeding model to study oral anticoagulants.

Dougald M Monroe¹, Maureane Hoffman¹

¹University of North Carolina Division of Hematology/Oncology, Chapel Hill, NC, USA; Duke University Department of Pathology, Durham, NC, USA.

Thrombosis Research

|April 25, 2014

Summary

New oral anticoagulants offer effective thrombosis prevention but pose bleeding risks post-trauma. A novel saphenous vein model accurately reflects bleeding defects from dabigatran at therapeutic levels.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mechanisms of thrombin inhibition by protein S and the TFPIα-fVshort-protein S complex.

Biophysical journal·2026

Same author

Evaluation of 3 commercial assays for the measurement of tissue factor activity in human plasma.

Research and practice in thrombosis and haemostasis·2026

Same author

Mechanisms of thrombin inhibition by protein S and the TFPIα-fVshort-protein S complex.

ArXiv·2025

Same author

The kinetics and interplay of thrombin inhibition by 4 plasma proteinase inhibitors.

Blood vessels, thrombosis & hemostasis·2025

Same author

True anticoagulation safety cannot be achieved without better anticoagulants.

BMJ open quality·2025

Same author

Mathematical analysis of emicizumab: affinity-driven complex formation and lipid-surface reactions.

Journal of thrombosis and haemostasis : JTH·2025

Area of Science:

Pharmacology
Hematology
Medical Devices

Background:

New oral anticoagulants (NOACs) provide alternatives to warfarin for thrombosis prevention.
While NOACs demonstrate comparable efficacy and reduced spontaneous bleeding, they present significant bleeding risks after trauma.
Current reversal agents for NOACs are unavailable, necessitating alternative management strategies.

Purpose of the Study:

To evaluate the efficacy of a novel hemostasis model in assessing bleeding complications associated with NOACs.
To establish a reliable animal model for studying the effects of dabigatran on hemostasis at therapeutic levels.
To provide a platform for testing potential reversal or bypassing agents for NOAC-induced bleeding.

Main Methods:

Utilized the Whinna saphenous vein hemostasis model.

More Related Videos

A Murine Model of Subarachnoid Hemorrhage

A Murine Model of Subarachnoid Hemorrhage

Published on: November 21, 2013

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

Related Experiment Videos

Last Updated: Apr 30, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

A Murine Model of Subarachnoid Hemorrhage

A Murine Model of Subarachnoid Hemorrhage

Published on: November 21, 2013

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

Administered dabigatran, a direct thrombin inhibitor, to induce a hemostatic defect.

Assessed bleeding severity at peak therapeutic dabigatran levels.

Main Results:

The Whinna saphenous vein model demonstrated a reliable reflection of hemostatic defects.
Increased bleeding was observed at therapeutic dabigatran levels within this model.
Previous models often required supratherapeutic doses to show bleeding effects.

Conclusions:

The Whinna saphenous vein hemostasis model is a viable tool for studying NOAC-induced bleeding.
This model can potentially evaluate the efficacy of bypassing agents in managing dabigatran-related bleeding.
Further research can utilize this model to develop effective interventions for managing bleeding complications associated with novel oral anticoagulants.